A glass structure 10 includes a pair of glass plates 11 and 12, a light control body 13 disposed between the pair of glass plates 11 and 12, and an ultraviolet absorbing layer 14 disposed between the light control body 13 and one of the glass plates 11. The ultraviolet absorbing layer 14 has a maximum transmittance of 10% or less in a wavelength region of 370 nm or more and 400 nm or less and a maximum transmittance of 50% or more in a wavelength region of more than 400 nm and 420 nm or less, and a ratio of a transmittance at 405 nm to a transmittance at 395 nm is 12 or more.

A glass structure 10 includes a pair of glass plates 11 and 12, a light control body 13 disposed between the pair of glass plates 11 and 12, and an ultraviolet absorbing layer 14 disposed between the light control body 13 and one of the glass plates 11. The ultraviolet absorbing layer 14 has a maximum transmittance of 10% or less in a wavelength region of 370 nm or more and 400 nm or less and a maximum transmittance of 50% or more in a wavelength region of more than 400 nm and 420 nm or less, and a ratio of a transmittance at 405 nm to a transmittance at 395 nm is 12 or more.

Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.

Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

Described herein are non-peptide drug conjugates (NPDCs) that target tumor cells expressing cell surface peptide and protein G protein-coupled receptors and their use in the treatment and/or diagnosis of cancer.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I: ##STR00001##
and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I: ##STR00001##
and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

The invention provides novel compounds and compositions comprising a 5-HT.sub.2B antagonist of formula I:

##STR00001##

and related methods for treating a person having a disorder characterized by undesirable 5-HT.sub.2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.